CNR2 and Hepatic fibrosis: In agreement with these findings, long-term administration of the CB2 agonist AM-1241 significantly inhibits PDGF signalling, reduces HSC activation and hepatic fibrosis, and improves hemodynamic function in fibrotic rats [104].